A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons

NCT00002130 · clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Otsuka America Pharmaceutical